US5070107A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Systemic antiviral treatment
Assignee: Avanir Pharmaceuticals Inc
•
Filing: 1989-11-02
•
Granted: 1991-12-03
•
Expires: 2009-11-02
Abstract
Abstract Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.
Inventors
- 👤 David H. Katz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 15:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/045; A61P; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 2
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 3
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 4
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 5
Independent Claim
64 words
A method of treating humans or other mammals for viral infections, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 6
Independent Claim
64 words
A method of treating humans or other mammals for viral infections, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 7
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 8
Independent Claim
63 words
A method of treating humans or other mammals for viral infections, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 9
Independent Claim
68 words
A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 10
Independent Claim
68 words
A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intravenous introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 11
Independent Claim
68 words
A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 12
Independent Claim
68 words
A method of preventing or inhibiting the infection of humans or other mammals for viral infections, comprising intramuscular introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 13
Independent Claim
66 words
A method of preventing or inhibiting the infection of humans or other mammals, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 14
Independent Claim
66 words
A method of preventing or inhibiting the infection of humans or other mammals, comprising trans-mucus membranal introduction into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 15
Independent Claim
65 words
A method of preventing or inhibiting the infection of humans or other mammals, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 16
Independent Claim
65 words
A method of preventing or inhibiting the infection of humans or other mammals, comprising transdermal penetration into the human or other mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible carrier.
Claim 17
Dependent Claim
43 words
A physiologically compatible solution which can be injected into humans or other mammals for viral infections intravenously or intramuscularly consisting essentially of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible, intravenously or intramuscularly injectable carrier.
Claim 18
Dependent Claim
43 words
A physiologically compatible solution which can be injected into humans or other mammals for viral infections intravenously or intramuscularly consisting essentially of a composition consisting of one or more C-27 to C-32 aliphatic alcohols in a physiologically compatible, intravenously or intramuscularly injectable carrier.
Claim 19
Dependent Claim
38 words
A physiologically compatible transdermal medication for introduction through the mucous membranes into humans or other mammals for viral infections consisting essentially of a composition consisting of one or more C-27 to C-32 aliphatic alcohols and a penetration-enhancing compound.
Claim 20
Dependent Claim
38 words
A physiologically compatible transdermal medication for introduction through the mucous membranes into humans or other mammals for viral infections consisting essentially of a composition consisting of one or more C-27 to C-32 aliphatic alcohols and a penetration-enhancing compound.
Claim 21
Independent Claim
43 words
A method of preventing conception and reducing the risk of viral infection comprising introducing a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons in a suitable carrier into the vagina substantially contemporaneously with or before intercourse.
Claim 22
Independent Claim
43 words
A method of preventing conception and reducing the risk of viral infection comprising introducing a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons in a suitable carrier into the vagina substantially contemporaneously with or before intercourse.
Claim 23
Dependent Claim
54 words
An anti-viral suppository for trans-membranal introduction into the vagina or anus of a human or other mammal of a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons in a physiologically acceptable carrier which is a solid at ambient room temperature and which melts at approximately 37° C.
Claim 24
Dependent Claim
54 words
An anti-viral suppository for trans-membranal introduction into the vagina or anus of a human or other mammal of a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons in a physiologically acceptable carrier which is a solid at ambient room temperature and which melts at approximately 37° C.
Claim 25
Independent Claim
93 words
A method of treating humans and mammals for viral infections comprising introducing a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons through a membrane into the circulatory system of a human or mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight comprising inserting such alcohol composition in a physiologically acceptable liquid, cream, gel or suppository carrier into the anus or vagina of the human or mammal to be treated.
Claim 26
Independent Claim
93 words
A method of treating humans and mammals for viral infections comprising introducing a composition consisting essentially of one or more aliphatic alcohols having from 27 to 32 carbons through a membrane into the circulatory system of a human or mammal suspected of having a viral infection with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight comprising inserting such alcohol composition in a physiologically acceptable liquid, cream, gel or suppository carrier into the anus or vagina of the human or mammal to be treated.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-02 | 1995-06-03 | 1995-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-02 | 1999-06-03 | 1999-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-02 | 2003-06-03 | 2003-12-03 | $7700.00 | Window Closed / Lapsed |